Total pendapatan perusahaan Altimmune (ALT)

Altimmune, Inc. (ALT) is a reputable developer of peptide-based obesity treatments. The company's consolidated sales on this chart help smooth out market noise, and 0.00 shows the value of this parameter. The business is fighting for market share by offering a unique dual mechanism of action for its drugs. Growth prospects rely on patents for the therapy of liver and metabolic diseases.

ALT - Pendapatan lan volume dodolan Altimmune, Inc. ing rentang 04.07.2022 - 13.11.2026

Rincian analitis perusahaan Altimmune, Inc.

- kuotasi lan prakiraan analis:

Bagan rega Altimmune Pharma|ALT - Bagan rega target

- rincian kapitalisasi pasar:

Nilai pasar Altimmune, Inc.|ALT - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham Altimmune|ALT - Kapitalisasi Buku|Kapitalisasi Pasar marang Nilai Buku altimmune.com|ALT - Aset Agregat Perusahaan

- data liabilitas lan likuiditas perusahaan:

Koefisien Total Utang marang Modal Altimmune, Inc.|ALT - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Altimmune Inc|ALT - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Altimmune, Inc.|ALT - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Altimmune|Rasio likuiditas perantara altimmune.com

- statistik bathi lan rasio pasar:

ALT - Bathi resik|Prakiraan bathi perusahaan Altimmune, Inc.|ALT - Rasio rega marang bathi|Prakiraan rega marang bathi altimmune.com|ALT - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Altimmune, Inc.|ALT - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Altimmune|ALT - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan altimmune.com|ALT - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Altimmune, Inc.

- statistik dodolan lan pendapatan perusahaan:

ALT - Dodolan perusahaan|Pendapatan mangsa ngarep perusahaan Altimmune Pharma|ALT - Multiplikator P/S|Rasio kapitalisasi marang dodolan sing dikarepake Altimmune, Inc.

Ringkesan analisis perusahaan:ALT, Altimmune Pharma

Altimmune, Inc. (ALT) is developing innovative peptide drugs to combat obesity, including the unique Pemvidutide. This indicator aggregates daily cash inflows from product sales, reflecting the real operational efficiency of the business. It is critical for investors to compare these flows with planned targets to assess the risks of asset drawdowns. The current value of the metric is 0.00. By analyzing the company's sales growth rate, one can determine the commercial success of the strategy to preserve patient muscle mass.

Analisis perusahaan pesaing